Equities researchers at JMP Securities started coverage on shares of Cogentix Medical, Inc. (NASDAQ:CGNT) in a report issued on Friday. The firm set an “outperform” rating and a $5.00 price target on the medical device company’s stock. JMP Securities’ price objective suggests a potential upside of 60.77% from the stock’s current price.

Separately, Zacks Investment Research upgraded Cogentix Medical from a “sell” rating to a “hold” rating in a report on Tuesday, July 4th.

Shares of Cogentix Medical (CGNT) opened at 3.11 on Friday. The company has a 50-day moving average price of $2.51 and a 200-day moving average price of $1.98. The firm’s market cap is $189.44 million. Cogentix Medical has a 12 month low of $1.37 and a 12 month high of $3.26.

Cogentix Medical (NASDAQ:CGNT) last posted its earnings results on Tuesday, August 1st. The medical device company reported $0.01 earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.01) by $0.02. Cogentix Medical had a negative return on equity of 13.83% and a negative net margin of 35.88%. The company had revenue of $14.06 million for the quarter, compared to analyst estimates of $13.90 million. Analysts forecast that Cogentix Medical will post ($0.03) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “JMP Securities Initiates Coverage on Cogentix Medical, Inc. (CGNT)” was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece of content on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright law. The correct version of this piece of content can be read at https://www.thecerbatgem.com/2017/10/08/jmp-securities-initiates-coverage-on-cogentix-medical-inc-cgnt.html.

Hedge funds have recently bought and sold shares of the company. Northern Trust Corp lifted its holdings in shares of Cogentix Medical by 0.4% in the second quarter. Northern Trust Corp now owns 73,926 shares of the medical device company’s stock valued at $129,000 after purchasing an additional 326 shares in the last quarter. Renaissance Technologies LLC lifted its holdings in shares of Cogentix Medical by 2.3% in the first quarter. Renaissance Technologies LLC now owns 562,996 shares of the medical device company’s stock valued at $1,013,000 after purchasing an additional 12,459 shares in the last quarter. Finally, Broadfin Capital LLC lifted its holdings in shares of Cogentix Medical by 45.2% in the second quarter. Broadfin Capital LLC now owns 1,094,544 shares of the medical device company’s stock valued at $1,905,000 after purchasing an additional 340,771 shares in the last quarter. Institutional investors own 12.67% of the company’s stock.

About Cogentix Medical

Cogentix Medical, Inc is a global medical device company. The Company designs, develops, manufactures and markets a line of fiber-optic and video endoscopy products under the PrimeSight brand that are used across various surgical specialties in diagnostic and treatment procedures. The Company also offers the Urgent PC Neuromodulation System (Urgent PC Systems), a device that delivers percutaneous tibial nerve stimulation (PTNS), for the office-based treatment of overactive bladder (OAB).

Receive News & Stock Ratings for Cogentix Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cogentix Medical Inc. and related stocks with our FREE daily email newsletter.